Despite advances in the management of cardiovascular disease (CVD), it remains the leading cause of death worldwide and a leading cause of disability. It also places a heavy burden on the patient and the community. Clinical trials that challenge current standards and open new potentials in management are therefore of great interest.
From the first presentation of the landmark
ONTARGET® trial results at the American College of Cardiology congress in Chicago, March 2008, a stream of trial results and publications have been released that demonstrate Pritor
®/Kinzal
®’s capacity to lead a change in hypertension and cardiovascular disease (CVD) management. Indeed, with outcome data from over 50,000 patients, Pritor
®/Kinzal
® has one of the largest evidence based data ever established for an angiotensin II receptor blocker (ARB).
The symposium, chaired by Prof. Giuseppe Mancia and Prof. João Morais, opened discussing the role of the renin-angiotensin aldosterone system (RAAS), its link with hypertension, CV and renal complications and the growing role of ARBs. Prof. Morais provided an overview of the
PROTECTION® program, highlighting the recently released meta-analysis results of
PRISMA™ I & II (Prospective, Randomised Investigation of the Safety & efficacy of telMisartan versus ramipril using ABPM).
